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ABSTRACT
Antibody-based immunotherapy represents a promising strategy to eliminate 
chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, 
we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its 
suitability as immunotherapy in AML. CD157 was expressed in 97% of primary AML 
patient samples. A significant, albeit lower expression level of CD157 was observed 
within the compartment of leukemia-initiating cells, which are supposed to be the 
major source of relapse. In healthy donor bone marrow, CD157 was expressed on 
CD34+ cells. In ex vivo assays, MEN1112 triggered natural killer (NK) cell-mediated 
cytotoxicity against AML cell lines and primary AML cells. Compared to its parental 
analogue, the Fc-engineered antibody exhibited higher antibody dependent cellular 
cytotoxicity responses. Using NK cells from AML patients, we observed heterogeneous 
MEN1112-mediated cytotoxicity against AML cells, most likely due to well-documented 
defects in AML-NK cells and corresponding inter-patient variations in NK cell function. 
Cytotoxicity could not be correlated to the time after completion of chemotherapy. In 
summary, we could demonstrate that CD157 is strongly expressed in AML. MEN1112 
is a promising antibody construct that showed high cytotoxicity against AML cells and 
warrants further clinical testing. Due to variability in NK-cell function of AML patients, 
the time of application during the course of the disease as well as combinatorial 
strategies might influence treatment results. 
INTRODUCTION
Overall survival of patients with acute myeloid 
leukemia (AML) has remained poor, despite decades of 
clinical studies. This is mainly due to residual leukemic 
cells, surviving standard chemotherapeutic regimens and 
inducing high relapse rates of > 50%. There is a high need 
to develop new treatment options. Immunotherapy has 
shown remarkable success for various cancer entities in 
recent years [1, 2], and antibody-based immunotherapeutic 
strategies are currently evolving quickly. 
The primary target antigen in AML has long been 
CD33. The most prominent anti-CD33 antibody in clinical 
application is gemtuzumab ozogamicin (GO, Mylotarg, 
Pfizer, New York, NY, USA), conjugated to calicheamicin. 
After a changeful history with accelerated approval in 
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2000 [3] and voluntary withdrawal from the market in 
2010 [4], a meta-analysis of five randomized controlled 
trials showed that the addition of GO to conventional 
chemotherapy significantly reduced the risk of relapse 
and resulted in a survival benefit for cytogenetically 
favorable and intermediate-risk group patients. However, 
a significant proportion of patients do still not benefit from 
GO treatment [5]. Apart from variations in linker and 
conjugation partners, the choice of the target antigen has 
the potential for further improvement of antibody-based 
therapy in AML.  
Antibodies directed at a multitude of antigens are 
under development, among others CD123 [6, 7], CLL-1 
[8, 9], CD44 [10, 11], and CD47 [12]. Here we report data 
on a new antibody directed at CD157. This molecule was 
originally cloned under the name of bone marrow stromal 
cell antigen 1 (BST-1) and found to facilitate pre-B-cell 
growth [13]. It is a glycosyl-phosphatidylinositol (GPI)-
anchored membrane protein with close resemblance to 
CD38 [14, 15]. CD157 is detectable on several cell types, 
such as dermal fibroblasts and peritoneal mesothelial 
cells, but mainly on myeloid cells in peripheral blood 
mononuclear cells (PBMCs) [16]. Flow cytometric 
analysis of normal bone marrow (BM) revealed that CD157 
expression becomes positive at the stage of CD34-/low 
myeloblasts and is high on more mature neutrophils and 
particularly on monocytic cells [17, 18].
With respect to hematological malignancies, CD157 
is significantly higher expressed on B-cell precursor acute 
lymphoid leukemia (ALL) cells compared to normal 
B-cell populations in the BM. 
In this study, we are the first to report data of 
CD157 expression on AML samples. CD157 could be 
validated as a strongly expressed target antigen in AML. 
Furthermore, we tested the ex vivo activity of MEN1112, 
an Fc-optimized anti-CD157 antibody.
MEN1112 induced efficient lysis of AML cell 
lines and primary AML cells ex vivo in an allogeneic and 
autologous setting. However, in comparison to healthy NK 
cells, we observed reduced cytotoxicity using NK cells 
from AML patients. 
Taken together, the results obtained in this study 
encourage further clinical development of MEN1112. 
RESULTS
CD157 is frequently expressed in primary AML 
patient samples
We first determined CD157 expression intensity 
(median fluorescence intensity; MFI ratio) on 8 AML 
cell lines. 7/8 cell lines were found to express surface 
CD157 (MOLM-13, HL60, MV4-11, Kasumi-1, OCI-
AML3, U937 and PL21). Positive cell lines (MFI ratio 
> 1.5) showed variable expression intensities of CD157, 
with PL21 showing the highest (median MFI ratio 8.6, 
n = 3) and MOLM-13 the lowest (median MFI ratio 1.8, 
n = 4) MFI ratio (Figure 1A). The intensity of CD157 
expression was further evaluated in 101 samples of newly 
diagnosed or relapsed AML patients. In 97% (98/101) 
of samples, positivity for CD157 could be demonstrated 
with substantial inter-patient heterogeneity in expression 
levels (Figure 1B). The direct comparison of CD157 and 
CD33 expression within the same patient cohort revealed 
lower expression of the former (n = 101, median MFI ratio 
CD33 vs CD157: 59.3 vs 12.5; Supplementary Figure 1). 
Due to relevant differences in antibody conjugated 
fluorochromes, statistical analysis was not performed. 
Comparison of CD157 expression at primary diagnosis 
and at time of relapse revealed no significant difference in 
expression intensity (n = 81 at primary diagnosis, n = 20 at 
relapse, p = 0.79, Figure 1C). To determine any correlation 
with cytogenetic or molecular disease characteristics, 
the patient cohort was subdivided into halves based on 
CD157 MFI ratio (Supplementary Figure 2). High CD157 
expression levels correlated with the prognostically 
adverse group of patients according to the European 
Leukemia Net (ELN) classification (p = 0.03). In contrast, 
no significant difference in prevalence among halves was 
determined for NPM1 and FLT3-ITD mutational status 
(p = 0.25) (Supplementary Figure 2). Among the entire 
patient cohort, CD157 expression was significantly 
different between FAB-subgroups (p = 0.0453) with M4 
and M5 subtypes showing the highest mean expression 
(mean MFI ratio 41.3 and 34.1, respectively) (Figure 1D).
As leukemia-initiating cells (LICs) – most frequently 
found within the CD34+/CD38- cell compartment – are 
supposed to be the source of relapse, we next analyzed 
the expression level of CD157 on CD45DIM, CD34+/CD38– 
cells of AML patients in comparison to leukemic bulk cells 
(CD45DIM). We found significantly lower CD157 expression 
on the former (median MFI ratio 4.3, n = 20) compared to 
the latter (median MFI ratio 7.7, p = 0.003; Figure 1E)
Comparison of CD34+ progenitor cells from HD BM 
to CD45DIM AML cells revealed no significant difference 
in CD157 expression level (p = 0.4; Figure 1F). 
MEN1112 shows high cytotoxicity against 
CD157+ AML cell lines
MEN1112-mediated cytotoxicity was evaluated 
in standard 4h Cr51 release experiments. Using HD NK 
cells, MEN1112 mediated cytotoxicity against OCI-
AML3 cells compared to control cultures in an effector to 
target (E:T) ratio-dependent manner (n = 3). Compared to 
MEN1112-triggered lysis of AML cells, non Fc-engineered 
Rituximab (anti-CD20 antibody) mediated reduced lysis 
of RAJI cells (CD20+ MFI ratio: 12.3), especially at low 
E:T ratios, despite equal surface expression intensities of 
their respective target antigens (n = 3; Figure 2A). Next, 
we determined the half maximum lysis capacity (EC50) for 
MEN1112 in dose response titration experiments using 
Oncotarget35709www.impactjournals.com/oncotarget
OCI-AML3 and U937 as target cells. MEN1112 mediated 
dose-dependent lysis of OCI-AML3 and U937 cells with a 
median EC50 of 2.35 µg/ml and 0.009 µg/ml, respectively 
(Figure 2B and Table 1). Furthermore, MEN1112 
demonstrated superior cytotoxic activity on U937 cells 
compared to its parental analogue, which was not enhanced 
for Fc-receptor binding (p < 0.0001; Figure 2C).
MEN1112 shows a trend towards higher 
cytotoxicity against AML cells compared to 
CD34+ BM progenitor cells 
As we have shown that CD157 is also expressed on 
CD34+ BM progenitor cells (see Figure 1), we evaluated 
the cytotoxic effects of MEN1112 on this cell population 
as well as on monocytes, which were also demonstrated 
to express CD157 [18]. The addition of MEN1112 to 
HD PBMCs resulted in dose-dependent elimination of 
monocytes within the sample (n = 2; Figure 3A). 
However, the direct comparison of OCI-AML3 cells, 
monocytes and CD34+ BM progenitor cells in coculture 
with HD NK cells revealed that MEN1112 shows a 
trend towards higher cytotoxicity against leukemic cells 
compared to CD157-expressiong healthy CD34+ BM 
progenitor cells (n = 6, Figure 3B). 
NK cells from AML patients show impaired 
antibody-mediated cytotoxicity compared to NK 
cells from HDs
We compared the cytotoxic potential of NK cells 
from HDs to those from AML patients using either the 
AML cell lines OCI-AML3 or U937 and MEN1112 or the 
lymphoma cell line RAJI and Rituximab. NK cells were 
obtained from AML patients at complete remission at 
different time points after completion of chemotherapy. In 
4 h Cr51 release cytotoxicity experiments, heterogeneous 
results could be obtained: In 2/9 samples, cytotoxicity of 
NK cells from AML patients was comparable to NK cells 
from HDs. In another sample, MEN1112-mediated lysis 
could be detected but was significantly reduced compared 
to NK cells from HDs. In the remaining 6 samples, no 
lysis of AML cells could be obtained using NK cells from 
AML patients. Cytotoxicity could not be correlated to time 
Figure 1: Ubiquitous CD157 expression in AML. (A + B) Flow cytometry-based CD157 expression analysis (A) on 8 AML 
cell lines and in (B) 101 primary AML patient samples at primary diagnosis or relapse. Median fluorescence intensity (MFI) ratio was 
determined as a measure of expression intensity (see Materials and Methods). The red line indicates an MFI ratio of 1.5, indicating 
CD157 positivity. (C) Comparison of CD157 expression intensity (MFI ratio) at primary diagnosis (n = 81) vs. relapse (n = 20; p = 0.79). 
(D) CD157 expression intensity correlated to French American British (FAB) subtypes (E) CD157 expression intensity (MFI ratio) on 
CD34+/CD38- leukemia initiating cells (LICs) compared to leukemic bulk cells (SSC/CD45DIM) (n = 20; p = 0.003) (F) Expression of 
CD157 on CD34+ bulk cells in bone marrow (BM) samples from healthy donors (HDs) (n = 14) compared to leukemic bulk cells (SSC/
CD45DIM) (n = 101). **p < 0.01, ****p < 0.0001, ns p > 0.5.
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Table 1: EC50 values of ADCC experiments








n.d., not determined, EC50, half maximal effective concentration.
Figure 2: MEN1112 mediates cytotoxicity against AML cell lines. (A–C) Standard 4h-Cr51 release cytotoxicity experiments 
using (A) different concentrations of HD natural killer (NK) cells (E:T ratios 50:1-6.25:1) and either CD157-expressing OCI-AML3 cells 
and MEN1112 (10 µg/ml; left panel) or CD20-expressing RAJI cells and Rituximab (10 µg/ml; right panel). Data represent mean ± SEM 
of 3 independent experiments (B) EC50 determination of MEN1112 in OCI-AML3 (left panel) and U937 (right panel) cells. The graphs are 
representative for 1 out of 3 experiments. EC50 values for all 3 experiments are listed in Table 1. (C) Cytotoxicity of MEN1112 against U937 
cells compared to its parental analogue (parental Ab). Fold change compared to target cells and NK cells without antibody is demonstrated. 
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after completion of chemotherapy. Table 2 and Figure 4 
summarize patient characteristics and corresponding 
results from cytotoxicity experiments.
MEN1112 induces lysis of primary AML cells in 
an allogeneic and autologous setting
Cytotoxicity of MEN1112 was tested against 
primary AML cells in an allogeneic and in an autologous 
system. First, HD NK cells were coincubated with primary 
AML cells and MEN1112 in 4 h Cr51 release experiments. 
MEN1112 induced cytotoxicity against primary AML cells 
in an E:T ratio-dependent manner (n = 5, Figure 5A and 
Table 2). However, cytotoxicity was lower compared to 
experiments using AML cell lines (see Figure 2), which 
might be explained by a higher spontaneous background 
lysis and potential evolving resistance mechanisms of 
primary AML cells. In an attempt to mimic the in vivo 
situation, we finally tested MEN1112 in an autologous 
set-up, using NK cells and primary AML cells from the 
same donor. First, we used CD33/CD34-depleted PBMCs 
from primary diagnosis as effector cells and corresponding 
CD33+/CD34+ cells as target cells. In this setting, only 
marginal lysis was detected (Figure 5B upper left panel 
and Table 2). In further experiments isolated NK cells 
from either primary diagnosis or from time of complete 
remission were used as effector cells. Indeed, we observed 
MEN1112-mediated cytotoxicity in this setting (Figure 5B 
upper right and lower left panel and Table 2). These results 
closely resemble the heterogeneous picture obtained with 
NK cells from AML patients in coculture with AML cell 
lines (see Figure 4).
DISCUSSION
Antibody-based immunotherapeutic strategies are 
currently entering the clinic for treatment of hematological 
malignancies including AML. Until now, CD33 was the 
most prominent and most often targeted antigen in AML 
[1, 2]. However, its rapid internalization into the cell 
upon receptor cross-linking makes it an unsuitable target 
for conventional antibody formats. Therefore, slow- or 
non-internalizing target antigens are needed to efficiently 
induce Fc-mediated effector functions. In the current study, 
we are the first to evaluate CD157 as a novel target antigen 
in AML. We could show that CD157 is expressed in 97% 
of AML patient samples with comparable prevalence 
and expression intensity at relapse compared to primary 
diagnosis. This is important, as numerous antibody-based 
immunotherapeutic strategies are preferentially used 
in relapsed/refractory patients. Furthermore, persistent 
expression of CD157 from primary diagnosis to relapse 
would provide the option for targeted therapy at any stage 
of the disease.
In our analysis correlating target antigen expression 
with genetic and molecular disease characteristics, we 
found equal expression intensities throughout all genetic 
risk profiles, with a tendency for higher expression in 
the ELN adverse group where novel immunotherapeutic 
approaches are most urgently needed. This makes CD157 
an attractive target for immunotherapy in AML. Another 
important aspect for targeted immunotherapy is the 
expression of CD157 on LICs, which are supposed to 
be the major source of relapse. Although CD34+/CD38- 
LICs showed significantly lower expression of CD157 
compared to AML bulk cells, the expression level was 
within the range of the AML cell lines used, indicating 
that this level is sufficient for recognition. Moreover, for 
CD33-targeted immunotherapy it was shown in vitro that 
target antigen expression levels only impair lysis kinetics 
but do not influence overall response to therapy [19, 20], 
suggesting that LICs can be eliminated through CD157-
targeted therapies. As shown by us and others, CD157 is 
expressed on CD34+ progenitor cells of the healthy BM 
compartment [17, 18]. The recently initiated phase I trial 
in relapsed/refractory AML (NCT02353143) will address 
Figure 3: Limited cytotoxicity of MEN1112 on healthy CD34+ bone marrow progenitor cells. (A + B) Flow cytometry-based 
cytotoxicity experiments using (A) healthy human peripheral blood mononuclear cells (PBMCs) incubated with MEN1112 or an irrelevant 
Fc-engineered control antibody (control antibody) (1.7-0.007 µg/ml) for 20-24 hours. Depletion of monocytes within the PBMC sample is 
shown. Data represent mean ± SEM of 2 independent experiments. (B) 24 hour-MEN1112 cytotoxicity assay using healthy donor (HD) NK 
cells and either OCI-AML3 cells, monocytes or CD34+ healthy bone marrow (BM) cells at an E:T ratio of 3:1. MEN1112 or the irrelevant 
Fc-engineered control antibody were added at 5 µg/ml.
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the question of dose and wanted on-target cytotoxicity 
versus unwanted off-tumor hematotoxicity. 
NK cells are promising effector cells for antibody-
mediated target cell lysis. Through the binding of their 
Fc part to Fc receptors on NK cells, antibodies of the 
IgG1 and IgG3 class can induce ADCC [21]. However, 
the physiological affinity between the Fc receptor of the 
NK cell and the Fc part of the antibody is low, to avoid 
unspecific and overwhelming immune reactions [22]. In 
recent years, a lot of effort has been made in engineering 
monoclonal antibodies to increase the affinity of the Fc 
part to the Fc receptor to induce stronger ADCC responses. 
Indeed, we could show that MEN1112 induced higher lysis 
of U937 target cells compared to its parental fucosylated 
analogue. Compared to Rituximab-mediated lysis against 
CD20-expressing RAJI cells, MEN1112 triggered more 
efficient lysis of OCI-AML3 target cells, despite equal 
antigen expression and especially at low E:T ratios. 
Obinutuzumab, a glycoengineered anti-CD20 antibody, has 
already demonstrated to induce stronger effector functions 
and target cell lysis compared to Rituximab [23, 24]. 
Moreover, MEN1112 was able to mediate cytotoxicity 
of primary AML cells in an allogeneic setting. This is of 
major importance, as it has been shown that AML cells 
are able to suppress immune responses through different 
mechanisms like secretion of immunosuppressive factors 
(i.e. arginase) [25]. Using NK cells from AML patients, 
MEN1112 induced ADCC in AML cell lines in 33% (3/9) 
samples tested. In an autologous setting using NK cells 
from primary diagnosis in two cases and from complete 
remission in another case, MED1112 induced ADCC 
responses were heterogeneous. Our data suggest that NK 
cells in AML are potentially impaired and are unable to 
mediate ADCC. During the course of the disease, NK 
cells might regain some of their function, albeit to a highly 
variable degree. In combinatorial studies using Rituximab 
in combination with lenalidomide, an increase of NK cell 
function including CD16 upregulation was observed [26]. 
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2 W 70 M4 + – normal favorable TAD/HAM pre-consolidation (2nd cycle) 0.0
3 M 17 M1 + – n.d. n.d. AraC+Daunorubicin (7 + 3)
post-consolidation 
(2nd cycle) 0.3
4 M 60 M4 + – normal favorable sHAM pre-consolidation (1st cycle) 43.3
5 M 80 M4 + – normal favorable AraC+Daunorubicin (7 + 3)
pre-maintanance 
(12th cycle) 1.4
6 M 67 M3 – – normal Intermediate I PETHEMA
pre-maintanance 
(1st cycle) 1.5
7 W 19 sAML – – complex adverse sHAM pre-maintanance (1st cycle)* 0.4
8 M 90 M4 + + normal Intermediate I n.a. HD 19.0
9 F 90 M1 + + aberrant Intermediate II n.a. HD 17.4
10 F n.d. n.d. n.d. n.d. n.d. n.d. n.a. HD 9.5
11 F 72 M1 + + normal Intermediate I n.a. HD 7.5
12 F 76 M1 + – normal favorable n.a. HD 10.9
13 M 42 M2 – – normal Intermediate I n.a. PD 6.9†
14 M 40 M2 n.d. n.d. n.d. n.d. n.a. PD 33.1†







*received no consolidation; PT, patient; PD, primary diagnosis; Dx, diagnosis;  M, male; F, female; FAB, French American British, ELN = European 
Leukemia Net; sHAM = sequential high dose cytarabine and mitoxantone; TAD = Thioguanin/Ara-C/Daunorubicin; HD = healthy donor;
PETHEMA = Idarubicin + All trans retinoic acid (ATRA); † % specific lysis at highest MEN1112 concentration; n.d., not determined; n.a., not applicable; 
PT 1–7 are depicted in Figure 4; PT 8-12 are depicted in Figure 5A; PT13-15 are depicted in Figure 5B; the last column refers to MEN1112 lysis against 
target cells in the specific experimental set-ups. 
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We hypothesize that combinatorial strategies using 
NK cell-recruiting antibodies with immunostimulatory 
substances might increase treatment success. Nevertheless 
the development strategy might be better clarified upon the 
availability of first-in-human (FIH) trial results. 
In summary, we could validate CD157 as a 
commonly expressed target antigen in AML and AML 
LICs at time of primary diagnosis and relapse. MEN1112 
induced efficient ADCC responses against CD157-
expressing AML cell lines and primary AML cells. Effector 
Figure 5: MEN1112 is able to mediate lysis of primary AML cells. (A–B) Standard 4-8h-Cr51 release cytotoxicity experiments 
using primary AML cells: (A) Coculture of primary AML cells with HD NK cells and MEN1112 (10 µg/ml) at different E:T ratios (50:1-
6.25:1). Data represent mean ± SEM of 5 experiments. (B) Coculture of primary AML cells with either autologous PBMCs from primary 
diagnosis (PBMC:AML cell ratio 80:1; upper left panel) or autologous NK cells from either primary diagnosis or complete remission 
(NK:AML cell ratio 20:1; upper right and lower left panel). MEN1112 was titrated in a 4-step serial dilution starting from 200 µg/ml. Target 
cells and NK cells without antibody served as negative control. 
Figure 4: Reduced antibody-mediated cytotoxicity using NK cells from AML patients. Standard 4h-Cr51 release cytotoxicity 
experiments using NK cells from healthy donors (HDs) vs AML patients (PT) in complete remission (at different time points within the 
treatment course) at different E:T ratios (50:1-3.125:1). The AML cell lines OCI-AML3 and U937 (closed squares or triangles) and the 
lymphoma cell line RAJI (open squares or triangles) were used as target cells. MEN1112 or Rituximab were used at 10 µg/ml. Target 
cells and NK cells without antibody served as negative control. Lysis efficacy was highly variable between AML patients but could not be 
correlated to time after completion of chemotherapy. Results from an E:T ratio of 25:1 are depicted in the graph.
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functions were increased compared to its fucosylated 
parental analogue. However, we could confirm previously 
reported NK-cell attenuation in AML. The relevance of 
our in vitro findings has to be addressed in a FIH trial. 
A phase 1 study has recently been initiated evaluating 
the use of MEN1112 in relapsed/refractory AML patients 
(NCT02353143). 
MATERIALS AND METHODS
Patients, diagnostics and AML risk stratification
After written informed consent in accordance 
with the Declaration of Helsinki and approval by the 
Institutional Review Board of the Ludwig-Maximilians-
Universität (Munich, Germany), peripheral blood (PB) or 
BM samples were collected from HDs and patients with 
AML at primary diagnosis or relapse. Patient characteristics 
are summarized in Table 2. Mononuclear cells from 
AML patients and HDs were isolated by density gradient 
centrifugation (Biochrom, Berlin, Germany) and either 
cryoconserved at < –80°C in 90% FCS and 10% dimethyl 
sulfoxide (Serva Electrophoresis, Heidelberg, Germany) or 
immediately used.
At diagnosis, a standard analysis of all samples 
was performed centrally at the Laboratory for Leukemia 
Diagnostics, University of Munich. This included 
cytomorphology, cytogenetics, fluorescence in situ 
hybridization and molecular genetics, performed as 
described previously [27–29].
Combined cytogenetic and molecular risk 
stratification groups were assigned in accordance with the 
European LeukemiaNet (ELN) guidelines [30].
Surface expression analysis
Surface expression of CD157 was assessed by 
flow cytometry (Navios, Beckman Coulter, Krefeld, 
Germany) using a fluorochrome-conjugated monoclonal 
antibody (SY11B5; e-Bioscience, San Diego, California). 
CD157 expression on CD34+/CD38- cells from BM of 
AML patients and HDs was analyzed using the following 
antibodies: CD45 (J33), CD34 (581), CD38 (LS198.4.3) 
and CD33 (D3HL60.251). Corresponding isotype controls 
were used. All antibodies were purchased from Beckman 
Coulter (Krefeld, Germany). A CD45DIM/SSCLOW gate was 
used to limit the analysis to myeloid progenitor cells.
Surface expression analysis of CD157 on AML 
cell lines and CD20 (clone 2H7, BioLegend, San Diego, 
California) on RAJI cells was performed on a BD LSR II 
(Becton Dickinson, Heidelberg, Germany). Staining was 
performed according to the manufacturer’s instructions.
MFI values were determined using FlowJo (Version 
9.4.11) (Tree Star Inc., Ashland, Oregon), and surface 
expression intensity (MFI ratio) was determined as 
previously described [20].
Cell lines
All AML cell lines and the lymphoma cell line 
RAJI were purchased from DSMZ (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen; Braunschweig, 
Germany) and cultured in RPMI1640 (PAN Biotech, 
Aidenbach, Germany), supplemented with 10% FCS 
and 1% penicillin/streptomycin/glutamine (GIBCO life 
technologies, Darmstadt, Germany), at 37°C and 5% CO2. 
Cell lines were screened by short tandem repeat (STR) 
profiling at DSMZ (Braunschweig, Germany) and tested 
for mycoplasma contamination at regular intervals.
MEN1112
The parental MEN1112 antibody was generated 
using Phage Display at Alere TM (San Diego, California). 
Binding of the lead candidate to cynomolgus and 
human Bst1/CD157 was confirmed by flow cytometry. 
Humanization of MEN1112 mouse Fab variable heavy (VH) 
and variable light (VL) amino acid sequences was carried 
out by JN Biosciences of Mountain View, California with 
proprietary sequence analysis and modeling methods. The 
humanized variable domain sequences were cloned into the 
Lonza GS expression construct with human heavy (IgG1) 
and light (kappa) constant region amino acid sequences to 
generate a stable cell line. The MEN1112_19C4 antibody 
producing cell line was generated using the Lonza GS 
System transfected into the BioWa Potelligent cell line 
by electroporation. Clones were selected according to the 
Lonza GS selection process. Positive clones were adapted 
to serum free conditions and clone 19C4 was selected, 
characterized and adapted for production. The stable cell 
line produced humanized non-fucosylated antibody against 
CD157. MEN1112 antibody-producing cells were grown in 
1-litre culture and supernatant was quantified for production 
and then purified on protein A column. Purified antibody 
was tested for quantity and quality by spectrophotometry 
(Nanodrop) and sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), respectively.
Antibody-dependent cellular cytotoxicity 
(ADCC)
MEN1112-mediated cytotoxicity was determined 
in standard 4–8h Cr51 release assays. Target cells (AML 
cell lines or primary AML cells) were labeled with 
50 µCi Cr51 (Hartmann Analytic, Braunschweig, Germany) 
for 90 minutes at 37°C. NK cells from HDs or AML 
patients at primary diagnosis or complete remission (CR) 
were negatively isolated (NK cell isolation kit, Miltenyi 
Biotech, Bergisch Gladbach, Germany) and added to 
the target cells at different E:T ratios (50:1–3.125:1) in 
triplicates. For autologous experiments, effector cells 
were either negatively isolated NK cells or CD33/CD34-
depleted PBMCs. MEN1112 or Rituximab were added at 
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a final concentration of 10 µg/ml. Rituximab was used 
as a non Fc-engineered control in some experiments as 
it represents a clinically established, therapeutic antibody 
with a validated target. Spontaneous lysis (Cr51-labeled 
target cells without NK cells and antibody) and maximum 
lysis (Cr51-labeled target cells directly on measurement 
plate) were determined in sextuplicates. 
Specific lysis was calculated using the following 
formula:  
After 4–8 hours of incubation at 37°C, supernatants 
were transferred to the measurement plate (Lumaplate, 
Perkin Elmer, Waltham, Massachusetts), dried overnight 
and analyzed using a TOPCount (Perkin Elmer, Waltham, 
Massachusetts) reader. For the determination of EC50 
values, NK cells were added at an E:T ratio of 25:1, and 
MEN1112 was titrated in a 12-step serial dilution (1:4) 
starting from 300 μg/ml. Target cells and NK cells without 
antibody served as background control. 
Flow cytometry 
Analysis of MEN1112 cytotoxicity against 
healthy cells was performed in either of the following 
experimental set ups: A) MEN1112 or an irrelevant Fc-
engineered control antibody were added to PBMCs at 
different concentrations (1.7–0.007 µg/ml) and incubated 
for 20–24 hours. B) CD34+ BM cells (CD34 Microbeads, 
Miltenyi Biotech, Bergisch Gladbach, Germany) from 
a HD or positive-selected CD14+ monocytes (CD14 
Microbeads, Miltenyi Biotech, Bergisch Gladbach, 
Germany) were incubated with negative-selected NK 
cells from an independent donor at an E:T ratio of 3:1 for 
24 hours. MEN1112 or an irrelevant Fc-engineered control 
antibody were added at 5 µg/ml. (A+B) Target cells and 
NK cells without antibody served as background control. 
Cultures were harvested, stained with fluorochrome–
labeled antibodies against CD33 (clone WM53) and 
CD56 (clone HCD56, BioLegend, San Diego, California) 
or CD16 (clone 3G8, BioLegend, San Diego, California) 
and analyzed by flow cytometry (BD LSR II; Becton 
Dickinson, Heidelberg, Germany). The percentage of 
CD33+ cells in untreated cultures relative to MEN1112 
or the irrelevant Fc-engineered control antibody treated 
cultures was used to determine the percentage of lysis. 
Statistical analysis
The significance of differences between the two 
halves of CD157 expression was determined by Pearson’s 
chi-squared test. The significance of differences between 
unpaired samples was determined by the two-tailed Mann-
Whitney U test. For pairwise comparison, the two-tailed 
Wilcoxon signed rank test was used. Dose response curve 
fits were performed using the GraphPad Prism software 
version 4 (GraphPad Software, Inc., La Jolla, California). 
Calculations were performed in either GraphPad Prism or 
IBM SPSS Statistics for Windows (Version 21.0, Armonk, 
New York). Results are shown as means ± standard error 
of mean (SEM) or as indicated. Statistical significance was 
considered for p < 0.05.
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